• 5 min read
• Published on 19 August 2025
Listen to article
6:19Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Let’s be honest, for the past year or so, you couldn’t move for hearing about the so-called miracle weight-loss jabs. Ozempic, Wegovy, you name it. The story seemed simple enough. A drug designed for diabetes turned out to be remarkably good at helping people shed a few pounds, and the world, or at least Hollywood, went mad for it. To me, it all felt a bit like a fad. But it turns out, we might have all been watching the warm-up act without realising the main event was about to begin.
The US Food and Drug Administration, not an institution known for its flights of fancy, just gave Wegovy the green light for something far more serious than fitting into last year’s trousers. They’ve approved it to treat a nasty liver condition called MASH. And that, I think, changes everything.
MASH, or metabolic dysfunction-associated steatohepatitis if you enjoy a mouthful, is a dreadful illness. It’s essentially a fatty liver that has become inflamed and scarred, and it can lead to cirrhosis and complete liver failure. For years, doctors have had precious few tools to fight it. This approval isn’t just a new tool, it’s a whole new toolbox.
What the FDA has done is validate an entirely new therapeutic approach. They’ve effectively said that these GLP-1 drugs, the science behind the weight-loss jabs, have a much wider role to play in our health. It’s like discovering your very reliable family car can also navigate choppy seas. Suddenly, its value and potential have multiplied. This regulatory nod could open the floodgates for a whole new wave of treatments and, consequently, investment.
For an investor, this is where it gets interesting. When a regulator like the FDA gives its blessing to a novel approach, it de-risks the entire field. It’s a signal flare to the market that this scientific path is worth exploring. Other companies with similar drugs in their pipelines just saw their chances of success improve dramatically.
Novo Nordisk, the Danish giant behind Wegovy, is obviously sitting pretty. They’ve proven their platform can do more than one trick, which is the holy grail for any pharmaceutical company. But the ripples will spread. You have more specialised players like Madrigal Pharmaceuticals and Sagimet Biosciences, who have been toiling away in the liver disease space for years. Suddenly, their niche area of expertise is front and centre, attracting a lot of new attention. It’s a classic tale of the tide rising and lifting all boats.
Now, before we all rush off and remortgage the house, a bit of perspective is needed. This is still the wild world of biotechnology. For every success story, there are a dozen failures littering the roadside. Clinical trials are fiendishly expensive and notoriously unpredictable. A promising drug can fall at the final hurdle, taking a company’s share price with it.
The market opportunity is enormous, no doubt. Millions suffer from liver disease, a problem sadly growing alongside obesity rates. But competition will be fierce. This approval simply fires the starting pistol on a new race. That’s why a targeted, yet diversified, approach makes sense. For those looking to get exposure to this specific medical breakthrough, a thematic basket like the GLP-1s Target Liver Disease basket could offer a way to spread the risk across the key players rather than betting on a single horse. It’s a pragmatic way to participate in what could be one of the most significant medical developments of the decade, without exposing yourself to the whims of a single company’s fortunes.
View the full Basket:GLP-1s Target Liver Disease
View the full Basket:GLP-1s Target Liver Disease
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 14 September 2026
Read article
Published on 14 September 2026
Read article
Published on 13 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article